Urinary ethyl glucuronide and ethyl sulfate testing for recent drinking in alcohol-dependent outpatients treated with acamprosate or placebo

Alcohol and Alcoholism

Volumn 46, Issue 5, 2011, Pages 553-557

  Dahl, Helen ^a   Hammarberg, Anders ^a   Franck, Johan ^a   Helander, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALCOHOL; ETHYL GLUCURONIDE; ETHYL SULFATE; PLACEBO; SULFATE; UNCLASSIFIED DRUG;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; DENIAL; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT DURATION; URINALYSIS;

ADULT; ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLICS; ALCOHOLISM; BIOLOGICAL MARKERS; BREATH TESTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DOUBLE-BLIND METHOD; ETHANOL; FEMALE; GLUCURONATES; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PLACEBOS; QUESTIONNAIRES; SUBSTANCE ABUSE DETECTION; SULFURIC ACID ESTERS; TAURINE; TIME FACTORS; YOUNG ADULT;

EID: 80051960498     PISSN: 07350414     EISSN: 14643502     Source Type: Journal    
DOI: 10.1093/alcalc/agr055     Document Type: Article

References (34)

1. Arndt T. (2001) Carbohydrate-deficient transferrin as a marker of chronic alcohol abuse: a critical review of preanalysis, analysis, and interpretation. Clin Chem 47:13-27.
2. Bortolotti F, De Paoli G, Tagliaro F. (2006) Carbohydrate-deficient transferrin (CDT) as a marker of alcohol abuse: a critical review of the literature 2001-2005. J Chromatogr B Analyt Technol Biomed Life Sci 841:96-109.
3. Dahl H, Stephanson N, Beck O et al. (2002) Comparison of urinary excretion characteristics of ethanol and ethyl glucuronide. J Anal Toxicol 26:201-4.
4. Drummond DC. (2001) Theories of drug craving, ancient and modern. Addiction 96:33-46.
5. Erim Y, Böttcher M, Dahmen U et al. (2007) Urinary ethyl glucuronide testing detects alcohol consumption in alcoholic liver disease patients awaiting liver transplantation. Liver Transpl 13:757-61.
6. Garbutt JC. (2009) The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat 36:S15-23.
7. Halter CC, Dresen S, Auwaerter V et al. (2008) Kinetics in serum and urinary excretion of ethyl sulfate and ethyl glucuronide after medium dose ethanol intake. Int J Legal Med 122: 123-8.
8. Hammarberg A, Jayaram-Lindström N, Beck O et al. (2009a) The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl) 205:53-62.
9. Hammarberg A, Nylander I, Zhou Q et al. (2009b) The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin. Brain Res 1305(Suppl):S2-6.
10. Hannuksela ML, Liisanantti MK, Nissinen AE et al. (2007) Biochemical markers of alcoholism. Clin Chem Lab Med 45:953-61.
11. Helander A. (2003) Biological markers in alcoholism. J Neural Transm 66(Suppl):15-32.
12. Helander A, Beck O. (2004) Mass spectrometric identification of ethyl sulfate as an ethanol metabolite in humans. Clin Chem 50:936-7.
13. Helander A, Beck O. (2005) Ethyl sulfate: a metabolite of ethanol in humans and a potential biomarker of acute alcohol intake. J Anal Toxicol 29:270-4.
14. Helander A, Zheng Y. (2009) Molecular species of the alcohol biomarker phosphatidylethanol in human blood measured by LC-MS. Clin Chem 55:1395-405.
15. Helander A, Beck O, Jones AW. (1996a) Laboratory testing for recent alcohol consumption: comparison of ethanol, methanol, and 5-hydroxytryptophol. Clin Chem 42:618-24.
16. Helander A, Voltaire Carlsson A, Borg S. (1996b) Longitudinal comparison of carbohydrate-deficient transferrin and gammaglutamyl transferase: complementary markers of excessive alcohol consumption. Alcohol Alcohol 31:101-7.
17. Helander A, von Wachenfeldt J, Hiltunen A et al. (1999) Comparison of urinary 5-hydroxytryptophol, breath ethanol, and self-report for detection of recent alcohol use during outpatient treatment: a study on methadone patients. Drug Alcohol Depend 56:33-8.
18. Helander A, Olsson I, Dahl H. (2007) Postcollection synthesis of ethyl glucuronide by bacteria in urine may cause false identification of alcohol consumption. Clin Chem 53:1855-7.
19. Helander A, Böttcher M, Fehr C et al. (2009a) Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol 44:55-61.
20. Helander A, Hagelberg CA, Beck O et al. (2009b) Unreliable alcohol testing in a shipping safety programme. Forensic Sci Int 189:e45-7.
21. Helander A, Kenan N, Beck O. (2010) Comparison of analytical approaches for liquid chromatography/mass spectrometry determination of the alcohol biomarker ethyl glucuronide in urine. Rapid Commun Mass Spectrom 24:1737-43.
22. Hermansson U, Helander A, Brandt L et al. (2010) Screening and brief intervention for risky alcohol consumption in the workplace: results of a 1-year randomized controlled study. Alcohol Alcohol 45:252-7.
23. Hoiseth G, Bernard JP, Stephanson N et al. (2008) Comparison between the urinary alcohol markers EtG, EtS, and GTOL/5-HIAA in a controlled drinking experiment. Alcohol Alcohol 43:187-91.
24. Hoiseth G, Yttredal B, Karinen R et al. (2010) Ethyl glucuronide concentrations in oral fluid, blood, and urine after volunteers drank 0.5 and 1.0 g/kg doses of ethanol. J Anal Toxicol 34:319-24.
25. Kiefer F, Jahn H, Tarnaske T et al. (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92-9.
26. Kiefer F, Helwig H, Tarnaske T et al. (2005) Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 11:83-91.
27. Mason BJ, Goodman AM, Dixon RM et al. (2002) A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 27: 596-606.
28. Morley KC, Teesson M, Reid SC et al. (2006) Naltrexone versus acamprosate in the treatment of alcohol dependence: a multicentre, randomized, double-blind, placebo-controlled trial. Addiction 101:1451-62.
29. Neumann T, Helander A, Dahl H et al. (2008) Value of ethyl glucuronide in plasma as a biomarker for recent alcohol consumption in the emergency room. Alcohol Alcohol 43:431-5.
30. Niemelä O, Alatalo P. (2010) Biomarkers of alcohol consumption and related liver disease. Scand J Clin Lab Invest 70:305-12.
31. Palmer RB. (2009) A review of the use of ethyl glucuronide as a marker for ethanol consumption in forensic and clinical medicine. Semin Diagn Pathol 26:18-27.
32. Schmitt G, Aderjan R, Keller T et al. (1995) Ethyl glucuronide: an unusual ethanol metabolite in humans. Synthesis, analytical data, and determination in serum and urine. J Anal Toxicol 19:91-4.
33. Stephanson N, Dahl H, Helander A et al. (2002) Direct quantification of ethyl glucuronide in clinical urine samples by liquid chromatography-mass spectrometry. Ther Drug Monit 24:645-51.
34. Verheul R, Lehert P, Geerlings PJ et al. (2005) Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl) 178:167-73.